{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-028595","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.655182+00:00","generated_at":"2026-05-15T11:25:47.072969+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fennec settles PEDMARK patent litigation; Cipla barred from generic until 2033","bullets":["Lawsuit dismissed; each party bears its own costs.","Cipla agrees not to launch generic sodium thiosulfate in U.S. until September 1, 2033, subject to earlier entry under specified circumstances.","Settlement covers Cipla's ANDA for generic PEDMARK, resolving litigation in D.N.J.","Press release issued March 16, 2026 announcing the agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-028595","json":"https://secwatch.observer/filing/0001104659-26-028595.json","markdown":"https://secwatch.observer/filing/0001104659-26-028595.md","text":"https://secwatch.observer/filing/0001104659-26-028595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465926028595/0001104659-26-028595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465926028595/fencf-20260316x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:25:47.072969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}